Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis

NCT00628433 is registered in ClinicalTrials.gov with Harbor Therapeutics as lead sponsor.

NCT NCT00628433
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00628433 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging Study of the Safety, Tolerance, Pharmacokinetics and Activity of HE3286 When Administered Orally to Patients With Active, Mild-to-Moderate Ulcerative Colitis
Lead sponsor
Harbor Therapeutics
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2008
Completion date
May 31, 2009
Enrollment
27 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis